New combo therapy shows promise for older hodgkin lymphoma patients
NCT ID NCT01476410
First seen May 27, 2026 · Last updated Jun 22, 2026 · Updated 5 times
Summary
This phase II trial tested a combination of the targeted drug brentuximab vedotin with standard chemotherapy (AVD) in 49 older adults with untreated Hodgkin lymphoma. The goal was to see if this approach could improve the number of patients whose cancer completely disappears. The study is complete, and results will help determine if this treatment is safe and effective for this age group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II ADULT HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan- Kettering Cancer Center
New York, New York, 10065, United States
-
NorthwesternU
Chicago, Illinois, 60611, United States
-
Stanford University Medical Center
Stanford, California, 94305, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198-7835, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brentuximab vedotin (a targeted antibody-drug) plus doxorubicin, vinblastine, and dacarbazine (chemotherapy)
What this could lead to
If successful, this combination could offer a more effective treatment option for older adults with Hodgkin lymphoma, potentially leading to higher remission rates.
What could go wrong
This is a small, early-phase trial with only 49 participants, so results may not apply to all patients. The combination may cause side effects like nerve damage or low blood counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.